Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy-Reference-Cited by-同舟云学术

Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy

Published:2007-01-01 Issue:11 Volume:45 Page:
ISSN:1437-4331
Container-title:Clinical Chemical Laboratory Medicine
language:
Short-container-title:

Author:

Lembessis Peter,Msaouel Pavlos,Halapas Antonis,Sourla Antigone,Panteleakou Zacharoula,Pissimissis Nikolaos,Milathianakis Constantine,Bogdanos John,Papaioannou Andreas,Maragoudakis Evangelos,Dardoufas Constantine,Dimopoulos Theodoros,Koutsilieris Michael

Abstract

AbstractClin Chem Leb Med 2007;45:1488–94.

Publisher

Walter de Gruyter GmbH

Subject

Biochemistry (medical),Clinical Biochemistry,General Medicine

Link

https://www.degruyter.com/document/doi/10.1515/CCLM.2007.301/pdf

Reference15 articles.

1. Upregulation of prostate - specific membrane antigen after androgen - deprivation therapy;Wright;Urology,1996

2. Validation of molecular targets in prostate cancer;Schalken;BJU Int,2005

3. Clinical utility of microarray - derived genetic signatures in predicting outcomes in prostate cancer;Reddy;Clin Genitourin Cancer,2006